CD8A and Zika virus infectious disease: Collectively, these data demonstrate that combinatorial treatment with anti-OX40 and anti–4-1BB agonist Abs promotes long-term immunity against ZIKV infection, primarily through CD8+ T cell–dependent mechanisms.